Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SRTS
stocks logo

SRTS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.35M
-36.14%
-0.055
-161.11%
8.23M
-1.35%
-0.050
-68.75%
9.25M
+26.46%
-0.010
-83.33%
Estimates Revision
The market is revising Upward the revenue expectations for Sensus Healthcare, Inc. (SRTS) for FY2025, with the revenue forecasts being adjusted by 1.22% over the past three months. During the same period, the stock price has changed by 20.44%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.34%
In Past 3 Month
Stock Price
Go Up
up Image
+20.44%
In Past 3 Month
Wall Street analysts forecast SRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTS is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTS is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.830
sliders
Low
6.00
Averages
7.00
High
8.00
Current: 3.830
sliders
Low
6.00
Averages
7.00
High
8.00
H.C. Wainwright
Buy
downgrade
$12 -> $8
2025-08-12
Reason
H.C. Wainwright
Price Target
$12 -> $8
2025-08-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Sensus Healthcare to $8 from $12 and keeps a Buy rating on the shares. The firm cites the company's Q2 sales miss for the target cut.
Lake Street
Buy
downgrade
$13 -> $6
2025-08-08
Reason
Lake Street
Price Target
$13 -> $6
2025-08-08
downgrade
Buy
Reason
Lake Street lowered the firm's price target on Sensus Healthcare to $6 from $13 and keeps a Buy rating on the shares. Q2 results fell below expectations and the firm's conclusion from its survey work that suggested upside to the quarter "was flat-out wrong," the analyst tells investors. However, the firm still believes "all roads ultimately lead to greater certainty and should benefit Sensus," the analyst added.
Maxim
Maxim
Buy
downgrade
$14 -> $10
2025-05-19
Reason
Maxim
Maxim
Price Target
$14 -> $10
2025-05-19
downgrade
Buy
Reason
Maxim lowered the firm's price target on Sensus Healthcare to $10 from $14 and keeps a Buy rating on the shares. The firm is updating its estimates to reflect the company's Q1 results and its expectations as well as citing its shift from a pure capital sales model to include its Fair Deal Agreement model, the analyst tells investors in a research note.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$12
2025-04-04
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$12
2025-04-04
Reiterates
Strong Buy
Reason
Lake Street
Ben Haynor
Strong Buy
Maintains
$18 → $13
2025-03-11
Reason
Lake Street
Ben Haynor
Price Target
$18 → $13
2025-03-11
Maintains
Strong Buy
Reason
Conference call with management will be held on March 4 at 3:30 pm hosted by Lake Street.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$11 → $12
2025-02-10
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$11 → $12
2025-02-10
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sensus Healthcare Inc (SRTS.O) is -32.00, compared to its 5-year average forward P/E of 9.81. For a more detailed relative valuation and DCF analysis to assess Sensus Healthcare Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
9.81
Current PE
-32.00
Overvalued PE
59.68
Undervalued PE
-40.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-72.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
315.13
Undervalued EV/EBITDA
-461.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.58
Current PS
0.00
Overvalued PS
3.61
Undervalued PS
1.55
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 4278.93% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 4278.93% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SRTS News & Events

Events Timeline

(ET)
2025-11-14
08:02:32
Sensus Healthcare names Michael Sardano as chief commercial officer
select
2025-11-06 (ET)
2025-11-06
16:46:17
Sensus Healthcare announces Q3 earnings per share of 6 cents, below consensus estimate of 11 cents.
select
2025-11-04 (ET)
2025-11-04
09:07:43
Sensus Healthcare Reveals CMS Treatment Codes for Superficial Radiotherapy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-07NASDAQ.COM
Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections

  • Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.

  • Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.

  • Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.

  • Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.

[object Object]
Preview
5.0
11-06Newsfilter
Sensus Healthcare Recognized as One of TIME's Growth Leaders in America for 2026

  • Recognition of Sensus Healthcare: Sensus Healthcare has been named No. 72 on TIME's list of America's Growth Leaders of 2026, highlighting its revenue growth, financial stability, and stock performance over the past five years.

  • Focus on Non-Invasive Treatments: The company specializes in non-invasive treatments for skin conditions, particularly non-melanoma skin cancer and keloids, utilizing its superficial radiation therapy (SRT and IG-SRT) technology.

  • CEO's Statement: Joe Sardano, CEO of Sensus Healthcare, emphasized the importance of customer service and patient outcomes in achieving this recognition, crediting the support from physicians and patients over the past 15 years.

  • Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, indicating that actual results may differ from expectations due to various factors affecting the business and industry.

[object Object]
Preview
5.0
10-31Newsfilter
Sensus Healthcare Reports the Death of Director Bill McCall

  • Passing of Bill McCall: Sensus Healthcare announces the passing of longtime friend and Director William "Bill" McCall, who played a crucial role in the company's development since 2009 and served on the Board since 2015.

  • Legacy and Contributions: Bill McCall was recognized for his financial acumen and leadership, significantly contributing to Sensus Healthcare's mission to provide patient-centric therapies, and was remembered as a trusted advisor and loyal friend.

  • Professional Background: McCall had a distinguished career in financial advisory and portfolio management, holding leadership positions at various firms and serving on multiple boards, including Cherokee Farm Partners.

  • Charitable Endeavors: Beyond his professional achievements, McCall was known for his charitable work, supporting educational and community organizations throughout Tennessee, leaving a lasting impact on both Sensus Healthcare and the community.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sensus Healthcare Inc (SRTS) stock price today?

The current price of SRTS is 3.83 USD — it has decreased -1.54 % in the last trading day.

arrow icon

What is Sensus Healthcare Inc (SRTS)'s business?

Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.

arrow icon

What is the price predicton of SRTS Stock?

Wall Street analysts forecast SRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTS is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sensus Healthcare Inc (SRTS)'s revenue for the last quarter?

Sensus Healthcare Inc revenue for the last quarter amounts to 6.88M USD, decreased -22.12 % YoY.

arrow icon

What is Sensus Healthcare Inc (SRTS)'s earnings per share (EPS) for the last quarter?

Sensus Healthcare Inc. EPS for the last quarter amounts to -0.06 USD, decreased -185.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sensus Healthcare Inc (SRTS)'s fundamentals?

The market is revising Upward the revenue expectations for Sensus Healthcare, Inc. (SRTS) for FY2025, with the revenue forecasts being adjusted by 1.22% over the past three months. During the same period, the stock price has changed by 20.44%.
arrow icon

How many employees does Sensus Healthcare Inc (SRTS). have?

Sensus Healthcare Inc (SRTS) has 35 emplpoyees as of December 13 2025.

arrow icon

What is Sensus Healthcare Inc (SRTS) market cap?

Today SRTS has the market capitalization of 62.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free